Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04485702 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Bioavailability Study of MELT-100 (Midazolam and Ketamine Sublingual) and IV Midazolam or Ketamine
A Phase 1 study, sponsored by Melt Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT04485702 is a Phase 1 study that has completed, run by Melt Pharmaceuticals. The registered enrollment target is 17 participants.
The verdict
NCT04485702, a Phase 1 study, has completed, sponsored by Melt Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
Comparative Bioavailability study testing MELT-100 (midazolam and ketamine sublingual tablet) and IV midazolam or ketamine in healthy volunteers
Interventions
- DRUG Midazolam injection
- DRUG Ketamine Injectable Product
- DRUG MELT-100
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2020-07-20 |
| Est. Completion | 2020-08-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04485702
The ClinicalTrials.gov registry entry for NCT04485702 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Melt Pharmaceuticals, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Midazolam injection is the first listed.
NCT04485702 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04485702 about?
NCT04485702 is a clinical study titled "Phase 1 Bioavailability Study of MELT-100 (Midazolam and Ketamine Sublingual) and IV Midazolam or Ketamine". Comparative Bioavailability study testing MELT-100 (midazolam and ketamine sublingual tablet) and IV midazolam or ketamine in healthy volunteers
What is the current status of trial NCT04485702?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2020-07-20. Estimated completion is 2020-08-29.
What interventions are being tested in trial NCT04485702?
The interventions under investigation include: Midazolam injection (DRUG), Ketamine Injectable Product (DRUG), MELT-100 (DRUG).
Who is sponsoring clinical trial NCT04485702?
This trial is sponsored by Melt Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.